Overview
Immunoproliferative Small Intestinal Disease (IPSID) is characterized by extra-nodal marginal zone B-cell lymphoma with villous atrophy in the small intestine, leading to chronic intermittent non-bloody diarrhea 1. Originally linked to the Mediterranean region, IPSID is now recognized globally, though diagnosis remains challenging due to limited scientific literature 1.Diagnosis
Clinical Presentation: Chronic intermittent non-bloody diarrhea 1.
Endoscopic Findings: Villous atrophy in the small intestine 1.
Histopathology: Characteristic lymphoplasmocytic infiltration in the lamina propria 1.
Diagnostic Tests: Biopsy of small intestinal mucosa is essential for definitive diagnosis 1.
Limited Diagnostic Tools: No specific non-invasive diagnostic tests widely validated 1.
Breath Hydrogen Testing: Not validated for IPSID diagnosis in veterinary medicine; further studies needed 2.Management
First-Line Treatment: Chemotherapy regimens such as CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) are commonly used 1.
Adjunctive Therapies: Supportive care including nutritional support and management of diarrhea 1.
Specific Drug Classes: No specific dosing mentioned in the reviewed literature 1.
Surgical Intervention: Reserved for complications such as obstruction or perforation 1.
Monitoring: Regular follow-up with endoscopic and histopathological assessments 1.
Outcome Monitoring: Evaluating response to therapy through clinical symptoms and laboratory markers 1.Special Populations
Pregnancy: No specific data provided in the reviewed abstracts 1.
Pediatrics: Not addressed in the provided abstracts 1.
Elderly: Management considerations similar to general population, with emphasis on supportive care due to potential comorbidities 1.
Comorbidities: Tailored management focusing on supportive care and addressing concurrent conditions 1.Key Recommendations
Definitive diagnosis requires small intestinal biopsy with histopathological examination (Evidence: Strong 1).
Chemotherapy, particularly CHOP regimen, is recommended as first-line treatment (Evidence: Moderate 1).
Regular clinical and endoscopic follow-up is crucial for monitoring disease progression and treatment response (Evidence: Moderate 1).References
1 Evangelista-Leite D, Affonso Madaloso B, Shouta Yamashita B, Enrico Aloise F, Polito Verdasca L, Lopes de Mello M et al.. Treating chronic diarrhea: A systematic review on Immunoproliferative Small Intestinal Disease (IPSID). PloS one 2021. link
2 German AJ, Martin MA, Papasouliotis K, Hall EJ. Assessment of a breath collection technique and portable breath hydrogen monitor for use in cats and dogs. Research in veterinary science 1998. link90172-2)